Furthermore, no significant differences in the levels of VEGF could be detected between ovarian cancer patients with different tumor grading (G1/G2 vs. G3), different nodal status (N0 vs. N1) or different hormone receptor status (ER/PGR positive vs. negative). This evidence concerns the gene VEGFA and ovarian cancer.